Monitoring and Managing Glucose Levels in People With Pancreatic Cancer

This study will investigate the prevalence of hyperglycemia (high blood sugar) in approximately 50 participants with pancreatic cancer. Sugar levels will be monitored with blood draws prior to each cycle of anti-cancer treatment until treatment ends or the participant's cancer worsens. Participants may receive any first-line systemic therapy for pancreatic cancer, including treatments given as part of another clinical trial. If treatment is needed to manage blood sugar levels, the treatment will be given according to the standard of care. All participants will be enrolled into the same group.

Trial Details

NCT ID
NCT05132244
Phase
NA
Sponsor
British Columbia Cancer Agency
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Endocrinologist-directed target blood glucose level 4-10 mmol/L using data from a continuous glucose monitor (CGM)
  • Standard Care
Locations (sample)
  • Vancouver, British Columbia, Canada|49.24966,-123.11934
  • Toronto, Ontario, Canada|43.65333,-79.38389

Key Eligibility Criteria

  • Histological/cytological diagnosis of pancreatic ductal adenocarcinoma (PDAC).
  • Planned to undergo first-line systemic therapy.
  • Age greater than or equal to 18 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →